Objective To compare the clinical efficacy, adverse reactions and MRI evaluation of neoadjuvant chemotherapy regimen do-cetaxel combined with epirubicin in sequential chemotherapy for locally advanced breast cancer. Methods A total of 120 patients with locally advanced breast cancer admitted to our hospital from January 2014 to January 2018 were selected and divided into two groups according to the random number table method. Each group included 60 cases. The control group was treated with epirubicin+ docetaxel +cyclophosphamide chemotherapy for four treatment cycles. The observation group was treated with epirubicin + cyclophosphamide as the control group during the first four cycles, but got docetaxel sequential therapy from the fifth treatment cycle. All patients were treated for 8 consecutive cycles. After treatment, evaluate and compare the clinical efficacy, adverse reactions and MRI evaluation. Results Compared with the control group, the total clinical effective rate of the observation group was significantly higher than that of the control group, and there was a significant difference be-tween the two groups (41.7% vs.66.7%, P0.05). Nausea and vomiting occurred in both groups, and the incidence was 100% in each group. MRI evaluation results showed that the diagnostic efficiency of the observation group was significantly higher than that of the con-trol group (P0.05);两组患者恶心、呕吐的发生率均达100%.观察组患者MRI诊断效能明显高于对照组,差异具有统计学意义(P<0.05).结论 多西紫杉醇联合表柔比星序贯化疗对局部进展期乳腺癌具有较好的临床疗效,且并未增加药物不良反应的发生,具有较好的安全性和耐受性.
展开▼
